Small and large PEGs greatly increase chemical potentials of globular proteins (μ2), thereby favoring precipitation, crystallization, and protein-protein interactions that reduce water-accessible protein surface and/or protein-PEG excluded volume. To determine individual contributions of PEG-protein chemical and excluded volume interactions to μ2 as functions of PEG molality m3 , we analyze published chemical potential increments μ23 = dμ2/dm3 quantifying unfavorable interactions of PEG (PEG200-PEG6000) with BSA and lysozyme. For both proteins, μ23 increases approximately linearly with the number of PEG residues (N3). A 1 molal increase in concentration of PEG -CH2 OCH2 - groups, for any chain-length PEG, increases μBSA by ∼2.7 kcal/mol and μlysozyme by ∼1.0 kcal/mol. These values are similar to predicted chemical interactions of PEG -CH2 OCH2 - groups with these protein components (BSA ∼3.3 kcal/mol, lysozyme ∼0.7 kcal/mol), dominated by unfavorable interactions with amide and carboxylate oxygens and counterions. While these chemical effects should be dominant for small PEGs, larger PEGS are expected to exhibit unfavorable excluded volume interactions and reduced chemical interactions because of shielding of PEG residues in PEG flexible coils. We deduce that these excluded volume and chemical shielding contributions largely compensate, explaining why the dependence of μ23 on N3 is similar for both small and large PEGs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485569 | PMC |
http://dx.doi.org/10.1002/bip.22662 | DOI Listing |
J Neurosurg
January 2025
1Department of Neurosurgery, Inselspital, Bern University Hospital, University Bern, Switzerland.
Objective: The effectiveness and optimal stimulation site of deep brain stimulation (DBS) for central poststroke pain (CPSP) remain elusive. The objective of this retrospective international multicenter study was to assess clinical as well as neuroimaging-based predictors of long-term outcomes after DBS for CPSP.
Methods: The authors analyzed patient-based clinical and neuroimaging data of previously published and unpublished cohorts from 6 international DBS centers.
Alzheimers Dement
December 2024
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Background: Current evidence suggests that hippocampal subfields have partially different genetic architecture and may improve the sensitivity of the detection of Alzheimer's disease (AD). In this study, we investigated whether genetic predisposition to AD contributes to the accelerated rate of hippocampal volume atrophy across sex and AD stages and how this contribution is specifically driven by functional variants located in the APOE gene.
Methods: The study comprised 1,051 participants from ADNI cohort (75.
Alzheimers Dement
December 2024
Institute of Linguistics, Academia Sinica, Taipei, Taiwan.
Background: The clinical progression of AD exhibits significant heterogeneity among individuals. Early identification of individuals likely to experience disease progression holds paramount importance within the context of a memory clinic. In the present study, we endeavor to analyze gait and speech data as potential predictors of early AD progression.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Stanford University School of Medicine, Stanford, CA, USA.
Background: Olfactory deficiency can be present in preclinical Alzheimer's (AD) and Parkinson's disease (PD), predicting their subsequent manifestation, including mild cognitive impairment (MCI). Analyzing key regions within the olfactory circuit could reveal important insights into the neuropathological progression. Dysfunction in the olfactory circuit has been shown in the olfactory nerve in limited postmortem studies, including involvement of a key region, the piriform cortex.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Population Health Sciences, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Background: Mental disorders have been linked to an increased risk of developing dementia including Alzheimer's disease. However, previous studies have typically focused on individuals who meet diagnostic criteria for a given psychiatric disorder. The goal of our study was to examine whether diverse neuropsychiatric symptoms are related to early markers of neurodegeneration in the general population.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!